The issue proceeds will be used to cover the completion of the ongoing Phase II trial of RP101 (SEK 6 million), business development / licensing of RP101 and general operating costs (SEK 3 million), cash repayment of the bridge loan from Formue Nord (SEK 1.5 million) and for the evaluation of new application areas for the Company's so-called delivery substance IntelliGel (SEK 1 million).